Table of Contents

• Glutamine Metabolism in Prostate Cancer

  Xuguang Guo

  Prostate cancer (PCa) is the most common malignancy in the urinary system. Research suggest that prostate cancer is often accompanied by gene mutations and metabolic reprogramming during disease progression, leading to disease advancement, metastasis, and therapeutic resistance. During metabolic reprogramming, glutamine serves as a carbon and nitrogen source to replenish the tricarboxylic acid cyc...

  REVIEW | Published: 04 Aug 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 3

  Pages: 83-89   PDF(1230KB)   Views：480Downloads：15

• Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Dedifferentiation: Clinico Pathological Significance- Review

  Sunil V. Jagtap, Shubham S. Jagtap ... Devika Borade

  Sarcomatoid and/or rhabdoid dedifferentiation are rare histopathological findings which may be heterogeneous in renal cell carcinoma. Sarcomatoid renal cell carcinoma shows marked cytologic atypia and containing enlarged pleomorphic and malignant spindle cells reminiscent of sarcoma. It is highly aggressive with a high metastatic potential and extremely poor prognosis. ...

  REVIEW | Published: 27 Aug 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 3

  Pages: 90-96   PDF(1900KB)   Views：2741Downloads：40

• Treatment Strategies for BCG Unresponsive Non-muscle Invasive Bladder Cancer

  Anusha Gupta, Shiv Verma, Sanjay Gupta

  Bacillus Calmette-Guérin (BCG) is the standard treatment for patients with non-muscle invasive bladder cancer (NMIBC). Although this therapy has been effective, BCG resistance poses a significant challenge, highlighting the need for alternative treatment options. Possible alternative treatments include intravesical chemotherapy, immunotherapy, antibody-drug conjugates, device-assisted therapies, g...

  REVIEW | Published: 29 Aug 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 3

  Pages: 97-109   PDF(957KB)   Views：430Downloads：21

• Research Progress of Neoadjuvant Chemotherapy in Advanced Bladder Cancer

  Haijun Hu, Xianghui Wu

  Systemic treatment, commonly referred to as chemotherapy, is a fundamental approach for treating muscle-invasive bladder cancer (MIBC) and metastatic bladder cancer. Neoadjuvant chemotherapy has recently become a standard treatment for MIBC, significantly reducing tumor recurrence rates and improving patient outcomes. Patients may receive adjuvant chemotherapy involving various drug combinations t...

  REVIEW | Published: 09 Sep 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 3

  Pages: 110-117   PDF(718KB)   Views：253Downloads：10

• Molecular and Clinicopathological Correlates of Wild-Type KRAS Expression in Prostate Cancer

  Henry O. Ebili, Sebastian A. Omenai ... Ngozi Chidozie

  The clinicopathological significance of KRAS alterations in clinical prostate cancer (PCa) has yet to be comprehensively studied, and the classic KRAS somatic mutations are rare in PCa. The clinico-genomic data of two PCa cohorts were retrieved from the cancer genome databases. KRAS expression-based gene enrichment for cell proliferation, apoptosis, and epithelial-mesenchymal transition /invasion ...

  RESEARCH | Published: 31 Jul 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 3

  Pages: 118-131   PDF(2470KB)   Views：473Downloads：13

• Comparative Analysis of PSA Nadir and Time to PSA Nadir on Clinical Outcomes in Patients with De Novo Spine Metastasis of Prostate Cancer Undergoing Androgen Deprivation Treatment (ADT) Only vs. ADT Intensification

  TAGANG Titus NGWA-EBOGO, Landry Oriol MBOUCHE ... Fru Forbuzshi ANGWAFO III

  Metastatic prostate cancer, particularly with bone involvement, is a severe form of the disease associated with poor prognosis. Androgen deprivation therapy (ADT) has been the standard treatment, but recent strategies suggest that ADT intensification may improve outcomes. This study evaluates the impact of ADT intensification on prostate-specific antigen (PSA) Nadir, time to PSA Nadir, and clinica...

  RESEARCH | Published: 16 Aug 2024

  Annals of Urologic Oncology, Volume 7 (2024), Issue 3

  Pages: 132-142   PDF(1056KB)   Views：352Downloads：9